A case of cancer-related hemolytic-uremic syndrome is reported. The patient presented a spontaneous recovery, which is unusual in this clinical picture. Mitomycin C is regarded as responsible for this toxic event in most cases. The case history reported here is discussed in relation to dose and scheduling of mitomycin C, and a safe maximum dosage in suggested.
Get full access to this article
View all access options for this article.
References
1.
AntmanK.H., SkarinA.T., MayerR.J., HargreavesH.K., CanellosG.P.: Microangiopathic hemolytic anemia and cancer: a review.Medicine, 58: 377–384, 1979.
2.
BrainM.C., AzzopardiJ.G., BakerL.R.I., PineoG.F., RobertsP.D., DacieJ.V.: Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma.Br. J. Haematol., 18: 183–193, 1970.
3.
BruntschU., GroosG., TiggesF.J., GallmeierW.M.: Microangiopathic haemolytic anemia, a frequent complication of mitomycin therapy in cancer patients.Eur. J. Cancer. Clin. Oncol., 20: 905–909, 1984.
4.
CantrellJ.E.Jr., PhillipsT.M., ScheinP.S.: Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.J. Clin. Oncol., 3: 723–734, 1985.
5.
FongJ.S.C., de ChadarevianJ.P., KaplanB.S.: Hemolyticuremic syndrome, current concepts and management.Pediatr. Clin. N. Am., 29: 835–856, 1982.
6.
FranchiF., BaroneC., GarufiC., SeminaraP., AstoneA., RicevutoE., CassanoA., GriecoA., BellantoneR., CocoC., CavallaroA., BossolaM.: Toxicity of the combination MMC/5-FU/folinic acid in adjuvant treatment of colorectal cancer.Medical Oncol. Tumor Pharmacother. In press.
7.
FrankW., OsterbergA.E.: Mitomycin C (NSC-26980) an evaluation of the Japanese reports.Cancer Chemother. Rep., 9: 114–119, 1960.
8.
GreenspanE.M., RatnerL.H.: Gastrointestinal cancer chemotherapy. In: Clinical Interpretation and Practice of Cancer Chemotherapy, GreenspanE.M. (Ed.), pp. 195–241. Raven Press, New York, 1982.
9.
JainS., SeymourA.E.: Mitomycin C associated hemolyticuremic syndrome.Pathology, 19: 58–61, 1987.
10.
JonesB.G., FieldingJ.W., NewmanC.E., HowellA., BrookesV.S.: Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C.Lancet, 2: 1275–1277, 1980.
11.
KarlinD.A., StoehleinJ.R.: Rash, nephritis, hypertension, and haemolysis in patients on 5-fluorouracil, doxorubicin, and mitomycin-C.Lancet, 2: 534–535, 1980.
12.
LempertK.D.: Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C.Lancet, 2: 369–370, 1980.
13.
LesesneJ.B., RothschildN., EricksonB., KorecS., SiskR., KellerJ., ArbusM., WoolleyP.V., ChiazzeL., ScheinP.S., NeefeJ.R.: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.J. Clin. Oncol., 7: 781–789, 1989.
14.
MergenthalerH.G., BinsackTh., WilmannsW.: Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5 fluorouracil-adriamycin-mitomycin C combination chemotherapy.Oncology, 45: 11–14, 1985.
